Company profilePharmaceutical#697 of 1,318 in Pakistan✓ No DRAP alerts

NEOPHAR HEALTH-CARE

Pharmaceutical company · 14 brands · 16 molecules

Ranked #22 of 35 companies in Anti-Acne Preparations

14 registered products 13 pharmaceutical brands 16 distinct molecules 0 DRAP alerts

Company overview

14
registered products
13
pharmaceutical brands
16
distinct molecules
5
therapeutic classes
0
DRAP alerts

NEOPHAR HEALTH-CARE is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 14 product registrations across 16 distinct molecules. Its portfolio is concentrated in Anti-Acne Preparations and Antifungal For Dermatological. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by NEOPHAR

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Anti-Acne Preparations 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20251

Top molecules by brand count

Minoxidil2 brands
Diclofenac1 brand
Adapalene1 brand
Sulphur1 brand
Permethrin1 brand

Therapeutic classes

Anti-Acne Preparations · 2Antifungal For Dermatological · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Skin Conditions · 1Other Dermatological Preparations · 1

Conditions treated

Acne/Oral · 1Hair Loss · 1

Price band (DRAP official ceilings)

Registered products priced by source
Servaid2 products · Rs 477 – Rs 608
Median across source: Rs 542.5

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Sante (Private) Limited10 shared molecules
BIO LABS (PVT) LTD.9 shared molecules
VALOR PHARMACEUTICALS9 shared molecules
DERMA TECHNO PAKISTAN9 shared molecules
PHARMA HEALTH8 shared molecules
Albro Pharmaceuticals7 shared molecules
CRYSTOLITE PHARMACEUTICALS7 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 136 molecules not in this portfolio
AlbendazoleAmikacinAmlodipineAmlodipine BasylateArtemetherAscorbic Acid
Sante (Private) Limited holds 79 molecules not in this portfolio
AcyclovirAmlodipineArtemetherAzithromycinAzithromycin Azithromycin DihydarteBenzoyl Peroxide
BIO LABS (PVT) LTD. holds 138 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate

Get the full profile for NEOPHAR

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.